CTOs on the Move

Editas Medicine

www.editasmedicine.com

 
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kevin Dushney
Vice President of Technology Profile
Vic Myer
Chief Technology Officer Profile

Funding

Editas Medicine raised $120M on 08/10/2015
Editas Medicine raised $215.6M on 06/23/2020
Editas Medicine raised $231M on 01/21/2021

Similar Companies

MicroConstants

MicroConstants, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tempest Therapeutics

Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.

Meissa Vaccines

Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.

Liphatech

Liphatech is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Escient Pharmaceuticals

Based in San Diego, we are led by an experienced team of entrepreneurs with deep roots in this region`s life sciences ecosystem and specific expertise in GPCR drug discovery and development. Escient Pharmaceuticals is supported by top-tier life-sciences investors with a proven track record for identifying and supporting successful, next-generation medicines companies.